open access

Vol 4, No 6 (2008)
Review paper
Published online: 2008-12-16
Get Citation

Influenza prophylaxis in a chosen population of cancer patients

Lidia B. Brydak
Onkol. Prak. Klin 2008;4(6):203-212.

open access

Vol 4, No 6 (2008)
REVIEW ARTICLES
Published online: 2008-12-16

Abstract

At present cancer is one of the most frequent causes of deaths not only in Poland but all over the world. In our country cancer is now the second most important cause of deaths preceded by circulatory diseases. Professor John Oxford once said: “You can stop having sex to prevent AIDS from spreading. But you can’t stop breathing”. Cancer patients need special care because their immunological system is weak. According to World Health Organisation data, every year 330-1,575 milion people are infected by the influenza virus, and 0.5-1 milion people die. Currently chromatographically pure inactivated vaccines against influenza and new generation anti-influenza drugs, ie neuraminidase inhibitors are available on the market. Vaccinations against influenza are recommended for people at high risk groups not only by Advisory Committee on Immunization Practiese but also by many scientific societies all over the world, including the American Cancer Society. This article presents the results of investigations in a selected population of cancer patients vaccinated with inactivated influenza vaccines. The author concludes that vaccinations against influenza in these groups of patients treated with different protocols are safe, effective and well tolerated. These results suggest that vaccinations can be recommended for cancer patients, depending on individual cases.

Abstract

At present cancer is one of the most frequent causes of deaths not only in Poland but all over the world. In our country cancer is now the second most important cause of deaths preceded by circulatory diseases. Professor John Oxford once said: “You can stop having sex to prevent AIDS from spreading. But you can’t stop breathing”. Cancer patients need special care because their immunological system is weak. According to World Health Organisation data, every year 330-1,575 milion people are infected by the influenza virus, and 0.5-1 milion people die. Currently chromatographically pure inactivated vaccines against influenza and new generation anti-influenza drugs, ie neuraminidase inhibitors are available on the market. Vaccinations against influenza are recommended for people at high risk groups not only by Advisory Committee on Immunization Practiese but also by many scientific societies all over the world, including the American Cancer Society. This article presents the results of investigations in a selected population of cancer patients vaccinated with inactivated influenza vaccines. The author concludes that vaccinations against influenza in these groups of patients treated with different protocols are safe, effective and well tolerated. These results suggest that vaccinations can be recommended for cancer patients, depending on individual cases.
Get Citation

Keywords

cancer; influenza; prophylaxis; influenza vaccine; high risk groups

About this article
Title

Influenza prophylaxis in a chosen population of cancer patients

Journal

Oncology in Clinical Practice

Issue

Vol 4, No 6 (2008)

Article type

Review paper

Pages

203-212

Published online

2008-12-16

Bibliographic record

Onkol. Prak. Klin 2008;4(6):203-212.

Keywords

cancer
influenza
prophylaxis
influenza vaccine
high risk groups

Authors

Lidia B. Brydak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl